Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

Summary

This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well it works when given alone or with chemotherapy. The study is for adults with early stage or locally advanced non-small cell lung cancer (NSCLC) that may or may not be removable with surgery. The study is seeking participants who: Are aged 18 years or older Have either: Early-stage or locally advanced (Stage II or IIIA/B) NSCLC and are a candidate for neoadjuvant therapy, followed by surgical removal of the tumor.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Carcinoma
• Non-Small-Cell Lung
• Lung Cancer (NSCLC)
• Lung Neoplasms
• Carcinoma, Non-Small-Cell Lung (NSCLC)
• Lung Disease
• Non-Small Cell Lung Cancer
• Non-small Cell Lung Cancer, Non-squamous
• Non-small Cell Lung Cancer, Squamous

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Pfizer

Last updated on ClinicalTrials.gov

October 8, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites